MarketCap
Facebook
X
Telegram
Beam Therapeutics Accounts Payables | BEAM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Beam Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 3.87 M | 1.62 M | 9.03 M | 7.47 M | 6.31 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 1.62 M | 6.42 M |
Quarterly Accounts Payables Beam Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.1 M | 12.3 M | 9.54 M | 10.6 M | 7.7 M | 3.87 M | 3.81 M | 4.43 M | 2.79 M | 1.62 M | 3.18 M | 6.89 M | 14.1 M | 9.03 M | 7.02 M | 7.1 M | 6.27 M | 7.47 M | 7.28 M | 8.03 M | 7.98 M | 6.31 M | 6.31 M | 6.31 M | 6.31 M | 7.85 M | 7.85 M | 7.85 M | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | 1.62 M | 7.26 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
13.2 M | $ 5.71 | 7.24 % | $ 700 M |  USA |
 |
AbbVie
ABBV
|
3.59 B | $ 261.51 | 1.66 % | $ 463 B | USA |
 |
Agenus
AGEN
|
83 M | $ 7.16 | 3.17 % | $ 213 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
1.76 M | - | -14.46 % | $ 27.9 M | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.69 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
7.89 M | $ 5.39 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 33.38 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
2.88 M | $ 3.29 | 2.94 % | $ 194 M |  China |
 |
iTeos Therapeutics
ITOS
|
8.5 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
2 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
6.47 M | $ 24.82 | 2.56 % | $ 3.77 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
14.7 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
5.49 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
457 K | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.59 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.17 M | $ 5.12 | 0.1 % | $ 981 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
9.18 M | $ 1.11 | 3.76 % | $ 141 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
655 K | $ 4.97 | 1.43 % | $ 3.32 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
10.9 M | $ 27.48 | 0.04 % | $ 4.63 B | USA |
 |
AIM ImmunoTech
AIM
|
1.63 M | $ 0.22 | 0.05 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
22.5 M | $ 9.15 | 0.16 % | $ 2.18 B | USA |
 |
Axcella Health
AXLA
|
4.71 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
2.51 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
10.1 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.23 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
1.95 M | $ 7.28 | 3.12 % | $ 317 M | USA |
 |
Baudax Bio
BXRX
|
3.2 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
732 K | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
3.83 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
1.84 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
6.75 M | - | - | $ 3.74 B | USA |
 |
Akebia Therapeutics
AKBA
|
21.2 M | $ 0.98 | 3.01 % | $ 252 M | USA |
 |
Avid Bioservices
CDMO
|
20.7 M | - | - | $ 789 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
11.9 M | - | - | $ 7.29 B | USA |
 |
Alector
ALEC
|
1.69 M | $ 2.22 | 3.74 % | $ 229 M | USA |